^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report

Published date:
09/30/2022
Excerpt:
We reported a 44-year-old woman with non-viral HCC...A truncating mutation FANCA p.Q1307fs was also observed. The tumor was microsatellite stable and had low tumor mutational burden of 4.5 muts/Mb….the patient started to use olaparib combined with low-dose cisplatin...follow-up CT scan showed stable disease. Her tumor did not progress until December 2020 with a progression-free survival of 12 months.
Secondary therapy:
cisplatin
DOI:
10.1097/MD.0000000000030719